Rochester Medical — Shareholder Meeting (January 2011)
20 slides from Rochester Medical's shareholder meeting presentation, Jan 27, 2011
Slide 1: Rochester Medical Corporation 2010/2011 Annual Shareowners Meeting
Rochester Medical Corporation 2010/2011 Annual Shareowners Meeting Minneapolis Hilton January 27, 2011 12:00 PM
Slide 2: Outline
Outline Corporate Overview Fiscal 2010, Q1 -2011 Pending Laprolan Acquisition 3 Year Plan to Double Sales
Slide 3: Company Facts
Company Facts Develop, Manufacture and Sell Disposable Incontinence and Bladder Drainage Devices Four Major Product Categories Rochester Medical Brand Sold in Over 75 Countries Focus on North America and Europe Private Label Sales to Major Medical Device Companies 33 Acres in Stewartville, Minnesota
Slide 4: Company Facts: Fully Vertically Integrated
Company Facts Fully Vertically Integrated Research and Development Quality and Regulatory Manufacturing/Process Design World Wide Sales, Marketing and Distribution Administration/Management Team
Slide 5: Company Facts: Strong Balance Sheet
Company Facts Strong Balance Sheet Cash $34M invested in safe, liquid investments $25M available on Line of Credit Working Capital $48.3M Low Debt ($1M) Will pay off debt associated with UK acquisition this Spring Positive Cash Flow
Slide 6: Sales - Brand Focused Growth, Private Label Stability
Sales -Brand Focused Growth Private Label "Stability" F05 F06 F07 F08 F09* F10 RM Branded 7351000 10797000 19226000 23848000 26331495 29759000 Private Label 8591000 10834000 13437000 11344000 11543445 11684000 *F09 if £ to $ exchange rates had not fallen (1.966 - 1.558)
Slide 7: Fiscal 2010 Sales Highlights
Fiscal 2010 Sales Highlights 28% Branded Sales Growth 19% Overall Sales Growth
Slide 8: Q1 2011 Sales Highlights
Q1 2011 Sales Highlights 18% Branded Sales Growth 8% Overall Sales Growth
Slide 9: Market Opportunity
Market Opportunity Products/Markets U.S. U.K. Rest of Europe Total Male External Catheter $50 $18 $60 $128 Intermittent $400 $100 $300 $800 FemSoft Foley Catheter TBD $400 TBD $50 TBD $70 TBD $520 TOTALS $850 $168 $430 $1,448 ($ in millions) Home Care Home Care Acute Care Home Care
Slide 10: Pending Laprolan B.V. Acquisition: Who is Laprolan?
Pending Laprolan B.V. Acquisition Who is Laprolan? 25 Year old Medical Distribution Company Located in the central region of The Netherlands Innovative patented products Urology, Wound and Scar Care, and Stoma Care Products
Slide 11: Pending Laprolan B.V. Acquisition: Who is Laprolan?
Pending Laprolan B.V. Acquisition Who is Laprolan? ROCM customer for over 16 years The Netherlands is the most densely populated country in the world with a population of 16M Deal to close mid April 2011, effective January 1, 2011 Strong group of seasoned, experienced employees
Slide 12: Pending Laprolan B.V. Acquisition: Who is Laprolan?
Pending Laprolan B.V. Acquisition Who is Laprolan? Strong Leadership Gerard deJong - former owner of Laprolan Now ROCM General Manager Calendar 2010 Sales of $11.2M EBIT of $3.5M Purchase Price $14.2M at current ER
Slide 13: Pending Laprolan B.V. Acquisition: Strategic Acquisition for ROCM
Pending Laprolan B.V. Acquisition Strategic Acquisition for ROCM Access to Mainland Europe Direct Sales Financial Strength Product Line expansion
Slide 14: The Future: Looking Ahead
The Future LOOKING AHEAD
Slide 15: 3 Year Plan to Double Sales and Create Significant Earnings
3 Year Plan to Double Sales and Create Significant Earnings Strong Focus on Branded Sales in Europe and US Primary Growth Drivers are: Intermittent Catheters Foley Catheters Acquisition Significant Branded Sales Force Expansion
Slide 16: Before (Fall 2010) US Sales Force
Before (Fall 2010) US Sales Force
Slide 17: Current (January 2011) US Sales Force
CURRENT (January 2011) US Sales Force
Slide 18: 3rd Year of Plan (2013)
3 Year Plan to Double Sales and Create Significant Earnings 3rd Year of Plan (2013) $83M Sales $9-10M After Tax Profit Much Greater Manufacturing Capacity Over $40M in Cash, subject to any further uses of cash, such as acquisitions if any
Slide 19: Summary
Summary Rochester Medical is in a strong position to achieve success Excellent Products Large Market R&D, Regulatory, Production, Administrative infrastructure in place Strong Sales and Marketing
Slide 20: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements" with the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the expected completion of the acquisition and financial results of Laprolan
Rochester Medical — Shareholder Meeting (January 2011) on 6ix